Rainier Group Investment Advisory LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 17.7% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 4,538 shares of the company’s stock after selling 976 shares during the period. Johnson & Johnson accounts for 0.3% of Rainier Group Investment Advisory LLC’s portfolio, making the stock its 20th largest position. Rainier Group Investment Advisory LLC’s holdings in Johnson & Johnson were worth $565,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the company. Adviser Investments LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $651,000. Greytown Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $433,000. Stellar Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $3,167,000. Asset Management One Co. Ltd. boosted its stake in shares of Johnson & Johnson by 1,147.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 4,946,229 shares of the company’s stock worth $569,967,000 after buying an additional 4,549,711 shares during the last quarter. Finally, Good Life Advisors LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,928,000. 66.10% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 132.63 on Friday. The company has a 50-day moving average price of $132.88 and a 200-day moving average price of $127.04. The stock has a market cap of $355.98 billion, a price-to-earnings ratio of 22.44 and a beta of 0.78. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $1.74 EPS. On average, equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 56.76%.
TRADEMARK VIOLATION NOTICE: This story was first posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/johnson-johnson-nysejnj-shares-sold-by-rainier-group-investment-advisory-llc-updated-updated.html.
A number of research analysts recently issued reports on the company. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reaffirmed a “hold” rating and set a $135.00 price target (down from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $134.12.
In related news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.